Rallybio Valuation

Is RLYB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RLYB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate RLYB's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate RLYB's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RLYB?

Key metric: As RLYB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RLYB. This is calculated by dividing RLYB's market cap by their current revenue.
What is RLYB's PS Ratio?
PS Ratio	37.8x
Sales	US$674.00k
Market Cap	US$25.45m

RLYB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RLYB's PS Ratio compare to its peers?

The above table shows the PS ratio for RLYB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	20.9x
HRGN Harvard Apparatus Regenerative Technology	40.7x	n/a	US$30.2m
EVAX Evaxion	3.6x	21.45%	US$27.9m
NEUP Neuphoria Therapeutics	1.4x	32.37%	US$21.8m
LSTA Lisata Therapeutics	37.7x	77.38%	US$40.3m
RLYB Rallybio	37.8x	68.11%	US$25.5m

Price-To-Sales vs Peers: RLYB is expensive based on its Price-To-Sales Ratio (37.8x) compared to the peer average (20.9x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does RLYB's PS Ratio compare vs other companies in the US Biotechs Industry?

126 Companies	Price / Sales	Estimated Growth	Market Cap
BIIB Biogen	2.9x	-0.44%	US$28.84b
INCY Incyte	3.9x	-1.49%	US$20.12b
BMRN BioMarin Pharmaceutical	3.7x	7.22%	US$11.50b
PTCT PTC Therapeutics	3.1x	0.35%	US$5.58b

126 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RLYB is expensive based on its Price-To-Sales Ratio (37.8x) compared to the US Biotechs industry average (11.3x).

Price to Sales Ratio vs Fair Ratio

What is RLYB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RLYB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	37.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RLYB's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystPriceTarget

Community Contributor

US$8

Fair Value

39.8% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/15 19:51
End of Day Share Price	2026/02/13 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rallybio Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Wolleben	Citizens JMP Securities, LLC
Eun Kyung Yang	Jefferies LLC
Catherine Novack	JonesTrading Institutional Services, LLC